Published in Gene Therapy Weekly, October 14th, 2004
The company's NAFTest for the detection, diagnosis, and monitoring of breast cancer utilizes fluids from the breast called nipple aspirates to identify groups of breast cancer proteins. Previous studies conducted by Power3 Medical using proteomic analysis of nipple aspirate fluid (NAF) found differences in the protein...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.